Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Alkem Laboratories Ltd. was founded in 1974 with a dream to improve the quality of
life with exceptional healthcare facilities and services.
Alkem, a leading generic and specialty drug manufacturer, is Indias seventh largest
pharmaceutical company with sales revenues exceeding USD 500 million, with a
CAGR of 16% over the last 5 years.
Alkem is a pioneer in the acute and chronic therapeutic segments with extensive
brand share in the Central Nervous System, Gastro-intestinal, Anti-diabetic, Antimalarial, Cardiovascular, Immunosuppressants, and Neutraceuticals segments.
Alkems success is highlighted by its leadership in the Anti-infective and Pain
Management segments. Of its portfolio of 800 brands, 3 brands, Taxim (Cefotaxim),
Clavam (Amoxicillin + Clavulanic Acid), and Sumo (Paracetamol) are ranked among
the top 25 brands in India, while 14 feature among the top 300 brands in the Indian
market.
Today, it covers both acute and chronic therapeutic segments with a diverse product
portfolio in every possible segment of the pharmaceuticals industry. Currently, its
products are marketed in 35 countries worldwide, with many more following soon.
Alkems strength lies in its ability to manufacture innovative products and envision
business potential in various segments, most recently, the health food market. The
range of products in this segment would largely be based on a wide range of
applications of FOS and Sucralose, a natural sweet tasting and sugar free, low
calorie sweetener. Moving ahead in this endeavour, Alkem has recently set up the
worlds largest Sucralose producing unit in India.
million and a healthy annual growth of over 20%. Over the past decade it has been
on an accelerated growth path in an increasingly competitive environment not just
in domestic markets but also in international markets.
Our Vision
In India, we are collaborating our combined efforts to regain and surge to the
coveted top 5 pharmaceutical companies by 2012. We wish to achieve this
milestone through organic growth and inorganically through international
partnerships and strategic alliances that would enhance our reach globally.
Our Mission
Our Values
Overall Strategy
Augmentation of product portfolio: Our quest for new products and concepts never
ends. We intend to further enhance our product portfolio across various therapy
areas in the Acute and Chronic segments.
Acute portfolio and Chronic portfolio: We currently enjoy a dominant position in the
Acute portfolio segment. Moving ahead in this segment, we plan to consolidate our
Acute portfolio and further tighten our hold in the market. Simultaneously, we are
concentrating our combined efforts to build our Chronic Portfolio. Overall, we intend
to create a good balance of Acute and Chronic driven therapy areas.
Continue focus on Brand Building: Brands are the strongest representator of our
company and Brand building is a critical success factor in todays competitive
scenario. We at Alkem have always understood this crucial business need and have
worked towards building the most envious brands in the Indian Pharmaceutical
industry. Today Alkem has almost 11 brands in the list of top 300 best selling
products of the industry. We also have over 28 brands worth more than $ 2 million
in our product portfolio.
Sweden
Gnosis
Switzerland
Oculus
The Netherlands
Reyon -
South Korea
Cargen
South Korea
USA
Switzerland
Product Profile
11 of our brands are listed in the top 300 brands in India, as per June 2011 IMS. We are rated as the
No.2 Company in the overall Antibacterial Segment and No.1 in Cephalosporin Formulations. We also
have a significant presence in several other therapy areas including Gastroenterology, Orthopaedics,
Oncology, Neuropsychiatry, Cardiovascular and Gynaecology, to mention a few. As a matter of fact, in
several of these segments, Alkem is considered to be a leader.
SBUs (Strategic Business Units)
At Alkem our domestic business is modelled through a strong and established therapy focused
Strategic Business Units (SBU's)
The following gives the therapy focus of the respective SBU's
Therapy focused SBU's
Ulticare
Bergen
Anti-infective
Antiinfective
Anti-infective
&
Bone Health
Division
Alkem
Pharma
Extra Urban
Division
Pentacare Neuroscience
Advanced
Neurology
Neurology
Respiratory
Division
Bergen Zurieve
Derma Care
Mediva
Gynecology and
Infertility
Cytomed
Oncology
Division
Aliva
Futura
Generic Division
Whilst in branded generics the Main Pharma Division, Ulticare and Bergen are the primary revenue
generators, the newer specialty divisions, Pentacare, Neurosciences (Neuropsychiatry), Mediva (Cardio
- Diabeto), Cytomed (Oncology) and Dermacare (Dermatology) are growing rapidly and are enhancing
their market share in the chronic segment space with a wide range of products in their respective
categories.
A substantial share in the generics business with two divisions catering (Alive/Futura) exclusively to the
generic business.
Alkem Pharma division is Alkems endeavour to venture in to the potential extra-urban space existing
in the Indian Pharma market.
Alkems offerings can be categorized as:
1) ACTIVE PHARMACEUTICAL INGREDIENT (API)
2) GENERIC PRODUCTS
3) BRANDED PRODUCTS
Alkems branded products enable people to lead a better quality of life. Alkems specialized
facilities and scientific resources help develop and manufacture products that are tailored to
address patient needs. As the branded business grows, Alkem continues to explore new areas
and exit platforms, in pursuit of enabling people live better lives.
Alkems stringent adherence to quality, coupled with its extensive marketing reach, has
enabled some of its brands to emerge as top brands in their respective segments. Today,
Alkem has over 800 branded products available across India.
Alkems brands lead in the Anti-infective, Gastro and Pain Management therapeutic areas, with
14 of them being ranked among the top 300 Indian brands.
Brand name
Therapeutic segment
"Anti-infective"
"Gastro"
"Gastro"
"Pain"
"Anti-infective"
4) NUTRACEUTICALS
Alkem Healthcare, a subsidiary of Alkem, offers a wide range of nutraceuticals a series of pharmabased nutritional food products. With the focus on providing solutions for Obesity, Diabetes, Cardiac &
Neurological problems, Alkem Healthcare endeavours to provide wholesome and functional health care
solutions, that are convenient to use and flavourful.
Alkem currently manufactures two sugar substitutes: Sucralose, which is a zero calorie sweetener;
and Fructo Oligosaccharide (FOS), which is a natural sweetener with prebiotic properties. FOS is also
approved as a soluble fibre neutraceutical which helps lowering LDL cholesterol levels to promote
cardiovascular health along with boosting immunity. For Sucralose, Alkem has developed a cost
effective, environment friendly, patent non-infringing process which conforms to USP-NF specifications
and is certified by the CFTRI & BAJAJ centre.
Nutraceuticals manufactured by Alkem include:
Jeevanprash
Jeevanprash is a sugar less, fat free natural food supplement. Jeevanprash contains FOS, instead of
sugar, while offering the same sweet taste; additionally, it contains 36 natural ingredients to improve
immunity, strength, stamina, vigour, and rejuvenation. Jeevanprash is also an excellent anti-ageing
tonic.
Jeevanprash is a good antioxidant that rids the body of toxins consumed every day through foods and
pollutants.
Fizzo
A Sucralose based antacid. It offers relief from symptoms of gas, indigestion & acidity, within seconds.
LEARNING EXPERIENCE
Stage 1: decartoning process